NVAX — Novavax, Inc.

NVAX Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenue: $70 million, down from $85 million in Q3 2024.
• Product Sales: $13 million from COVID vaccine and Matrix-M supply sales.
• Royalties and Other Revenue: $57 million, primarily from the Sanofi agreement, including $46 million in R&D reimbursement.
• Net Loss: $202 million, or $1.25 per diluted share.
• Cash Position: $812 million in cash and accounts receivable at the end of Q3.
• Cost Reduction: Combined R&D and SG&A expenses reduced by 18% year-over-year, with SG&A down 55%.

2. Strategic Updates and Business Highlights

• Novavax is transitioning from a COVID-19 vaccine-focused organization to a diversified biopharmaceutical company emphasizing partnerships and R&D innovation.
• Significant partnerships include an expanded collaboration with Sanofi, which now handles the commercial responsibilities for Nuvaxovid in the U.S. and select markets.
• The company has achieved $1.1 billion in nondilutive cash flow over the past eight quarters, including $800 million from partnerships.
• New early-stage R&D programs launched targeting C. diff, shingles, RSV combination, and pandemic flu, with promising preclinical data emerging.

3. Forward Guidance and Outlook

• 2025 Financial Guidance: Reaffirmed adjusted total revenue guidance of $1.040 billion to $1.060 billion, excluding certain revenues.
• 2026 Revenue Framework: Expected adjusted total revenue of $185 million to $205 million, including a $75 million milestone from manufacturing tech transfer to Sanofi.
• Path to Profitability: Non-GAAP profitability targeted as early as 2028, contingent on successful development and commercialization of pipeline products.

4. Bad News, Challenges, or Points of Concern

• Declining COVID Vaccine Demand: The COVID-19 vaccine market is experiencing a decline, with a 20% reduction in prescriptions compared to the previous year.
• Transition Year Risks: 2025 is characterized as a transition year for Sanofi's commercialization of Nuvaxovid, leading to uncertainty in sales performance.
• Regulatory Dependencies: Future profitability is heavily reliant on the successful execution of Sanofi's plans and regulatory approvals for combination vaccines.
• Noncash Charges: The company incurred $126 million in noncash charges related to site consolidation and debt refinancing, which could raise concerns about financial stability.

5. Notable Q&A Insights

• COVID Season Feedback: The company noted a 20% decline in the COVID vaccine market, with Sanofi expected to optimize marketing strategies moving forward.
• BARDA Grant: Discussed a BARDA grant awarded to Sanofi for pandemic flu vaccine development using Novavax's Matrix-M adjuvant, indicating potential future revenue streams.
• Pipeline Strategy: The company is focused on early-stage pipeline programs, with plans to out-license assets and explore partnerships to maximize their technology's potential.
• Market Competition: There was acknowledgment of competitive pressures in the shingles vaccine market, with Novavax aiming to differentiate based on tolerability and efficacy.
• Cost Structure: Significant reductions in operating expenses are expected as transition activities with Sanofi conclude, with a target of $250 million in net expenses by 2027.

This summary encapsulates the key aspects of Novavax's Q3 2025 earnings call, highlighting financial performance, strategic initiatives, future outlook, and challenges faced by the company.